Nemours Children's Clinic
nemours.orgTotal trials
124
Active
29
Phase 3
7
Total enrollment
15,809
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lidocaine | — | — | — | — | — | 1 | |
| Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution | — | — | — | — | — | 1 | |
| Sodium Chloride 0.9% Inhl 3Ml | — | — | — | — | — | 1 | |
| GLP-1 Receptor Agonists | — | — | — | — | — | 1 |
Next readouts
- 2026-12
- 2028-12
- 2029-12-31
Top conditions
- Asthma10
- Type 1 Diabetes Mellitus8
- Obesity7
- Diabetes Mellitus, Type 16
- Type 1 Diabetes4
- Idiopathic Short Stature3
- Spinal Muscular Atrophy3
- Pediatric Obesity3
Frequently asked questions about Nemours Children's Clinic
- How many clinical trials does Nemours Children's Clinic have on ClinicalTrials.gov?
- Nemours Children's Clinic is listed as the lead sponsor on 124 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Nemours Children's Clinic's trials are in Phase 3?
- 7 of Nemours Children's Clinic's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Nemours Children's Clinic focus on?
- Nemours Children's Clinic's most-studied conditions on ClinicalTrials.gov are Asthma, Type 1 Diabetes Mellitus, Obesity, Diabetes Mellitus, Type 1, Type 1 Diabetes.
- When are Nemours Children's Clinic's next clinical trial readouts?
- Nemours Children's Clinic has 3 upcoming primary-completion readouts tracked here; the soonest is “Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)”, expected around 2026-12.